Browsing by Subject "Personalized chemotherapy"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Contemporary management of muscle-invasive bladder cancer
    (Taylor & Francis, 2012) Dall’Era, Marc A.; Cheng, Liang; Pan, Chong-Xian; Pathology and Laboratory Medicine, School of Medicine
    The current standard treatment for muscle-invasive nonmetastatic bladder cancer is neoadjuvant platinum-based chemotherapy followed by radical cystectomy. However, neoadjuvant chemotherapy is not widely accepted even with level 1 evidence. Adjuvant chemotherapy should be discussed if patients have not received neoadjuvant chemotherapy before surgery and have high-risk pathologic features. Although not considered standard of care, bladder-sparing therapy can be considered for highly selected patients and for those medically unfit for surgery. Even though there are no level 1 data, the treatment outcomes for highly select patients given bladder-sparing therapy appear promising, with many patients retaining a functional bladder. Personalized chemotherapy is currently being actively pursued to target the underlying molecular changes and tailor to individual needs.